Combinatorial approaches for novel cardiovascular drug discovery: a review of the literature

References

• Jia J, Zhu F, Ma X, et al. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 2009 Feb;8(2):111–128.
   PubMed Web of Science ®Google Scholar
• Pemovska T, Bigenzahn JW, Superti-Furga G. Recent advances in combinatorial drug screening and synergy scoring. Curr Opin Pharmacol. 2018 Oct;42:102–110.
   PubMedGoogle Scholar
• Herrick TM, Million RP. Tapping the potential of fixed-dose combinations. Nat Rev Drug Discov. 2007 Jul;6(7):513–514.
   PubMedGoogle Scholar
• Hens B, Corsetti M, Bermejo M, et al. “Development of fixed dose combination products” Workshop report: considerations of gastrointestinal physiology and overall development strategy. AAPS J. 2019 Jun 6;21(4):75.
   PubMedGoogle Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007 Aug;120(8):713–719.
   PubMed Web of Science ®Google Scholar
• Connor J, Rafter N, Rodgers A. Do fixed-dose combination pills or unit-of-use packaging improve adherence? A systematic review. Bull World Health Organ. 2004 Dec;82(12):935–939.
   PubMed Web of Science ®Google Scholar
• Aslam F, Haque A, Lee V, et al. Patient adherence and preference considerations in managing cardiovascular risk: focus on single pill and amlodipine/atorvastatin fixed combination. Patient Prefer Adherence. 2009 Nov 3;3:61–66.
   PubMedGoogle Scholar
• Bramlage P, Schmidt S, Sims H. Fixed-dose vs free-dose combinations for the management of hypertension-An analysis of 81 958 patients. J Clin Hypertens (Greenwich). 2018 Apr;20(4):705–715.
   PubMedGoogle Scholar
• Godman B, McCabe H, DL T. Fixed dose drug combinations - are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Rev Pharmacoecon Outcomes Res. 2020 Feb;20(1):1–26.
   PubMed Web of Science ®Google Scholar
• Das P, Delost MD, Qureshi MH, et al. A survey of the structures of US FDA approved combination drugs. J Med Chem. 2019 May 9;62(9):4265–4311.
   PubMedGoogle Scholar
• Bayat Mokhtari R, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017 Jun 6;8(23):38022–38043.
   PubMedGoogle Scholar
• Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014 Dec 19;346(6216):1480–1486.
   PubMedGoogle Scholar
• Plana D, Palmer AC, Sorger PK. Independent drug action in combination therapy: implications for precision oncology. Cancer Discov. 2022 Mar 1;12(3):606–624.
   PubMedGoogle Scholar
• Bush KT, Boichard A, Tsigelny IF. In vitro elucidation of drug combination synergy in treatment of pancreatic ductal adenocarcinoma. Anticancer Res. 2018 Apr;38(4):1967–1977.
   PubMed Web of Science ®Google Scholar
• Ali MA, Rizvi S, Syed BA. Trends in the market for antihypertensive drugs. Nat Rev Drug Discov. 2017 May;16(5):309–310.
   PubMedGoogle Scholar
• Cummings JL, Tong G, Ballard C. Treatment combinations for Alzheimer’s disease: current and future pharmacotherapy options. J Alzheimers Dis. 2019;67(3):779–794.
   PubMed Web of Science ®Google Scholar
• Barthold D, Joyce G, Diaz Brinton R, et al. Association of combination statin and antihypertensive therapy with reduced Alzheimer’s disease and related dementia risk. PLoS One. 2020;15(3):e0229541.
   PubMedGoogle Scholar
• Ortiz-Orendain J, Castiello-de Obeso S, Colunga-Lozano LE, et al. Antipsychotic combinations for schizophrenia. Cochrane Database Syst Rev. 2017 Jun 28;6: CD009005. DOI:10.1002/14651858.CD009005.pub2.
   PubMedGoogle Scholar
• Teng D, Gong Y, Wu Z, et al. In silico prediction of potential drug combinations for Type 2 diabetes mellitus by an integrated network and transcriptome analysis. ChemMedChem. 2022 Feb 4;17(3):e202100620.
   PubMedGoogle Scholar
• Mulani MS, Kamble EE, Kumkar SN, et al. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review. Front Microbiol. 2019;10:539.
   PubMed Web of Science ®Google Scholar
• Ghosn J, Taiwo B, Seedat S, et al. Hiv. Lancet. 2018;392(10148):685–697.
   PubMed Web of Science ®Google Scholar
• Tan X, Hu L, Luquette LJ 3rd, et al. systematic identification of synergistic drug pairs targeting HIV. Nat Biotechnol. 2012 Nov;30(11):1125–1130.
   PubMed Web of Science ®Google Scholar
• van Wijk RC, Ayoun Alsoud R, Lennernäs H, et al. Model-informed drug discovery and development strategy for the rapid development of anti-tuberculosis drug combinations. Appl Sci. 2020;10(7):2376.
   Google Scholar
• Day D, Siu LL. Approaches to modernize the combination drug development paradigm. Genome Med. 2016 Oct 28;8(1):115.
   PubMedGoogle Scholar
• Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015 Jul 16;373(3):209–219.
   PubMedGoogle Scholar
• Armitage JO, Armitage JO. Treatment of non-Hodgkin’s lymphoma. N Engl J Med. 1993 Apr 8;328(14):1023–1030.
   PubMedGoogle Scholar
• Palella FJ Jr., Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med. 1998 Mar 26;338(13):853–860.
   PubMedGoogle Scholar
• Jin W, Stokes JM, and Eastman RT, et al. Deep learning identifies synergistic drug combinations for treating COVID-19. Proc Natl Acad Sci U S A. 2021 Sep 28;118(39):e2105070118 . DOI:10.1073/pnas.2105070118.
   PubMedGoogle Scholar
• Nafshi R, and Lezon TR. Predicting the effects of drug combinations using probabilistic matrix factorization. Front Bioinform. 2021;1:708815.
   PubMedGoogle Scholar
• Brogi S, Calderone V. Artificial intelligence in translational medicine. Int J Transl Med. 2021;1(3):223–285.
   Google Scholar
• Cheng F, Kovacs IA, Barabasi AL. Network-based prediction of drug combinations. Nat Commun. 2019 Mar 13;10(1):1197.
   PubMedGoogle Scholar
• Caskey CT. The drug development crisis: efficiency and safety. Annu Rev Med. 2007;58(1):1–16.
   PubMedGoogle Scholar
• Vasaikar S, Bhatia P, Bhatia PG, et al. Complementary approaches to existing target based drug discovery for identifying novel drug targets. Biomedicines. 2016 Nov 21;4(4):27.
   PubMedGoogle Scholar
• Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004 Aug;3(8):673–683.
   PubMed Web of Science ®Google Scholar
• Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020 Dec 22;76(25):2982–3021.
   PubMed Web of Science ®Google Scholar
• Savoji H, Mohammadi MH, Rafatian N, et al. Cardiovascular disease models: a game changing paradigm in drug discovery and screening. Biomaterials. 2019 Apr;198:3–26.
   PubMed Web of Science ®Google Scholar
• Fishback DB, Castor LH. The use of chlorothiazide or hydrochlorothiazide with reserpine in the office treatment of hypertension. Dis Chest. 1961 Aug;40(2):203–209. .
   PubMedGoogle Scholar
• Burris JF, Davidov ME, Jenkins P, et al. Comparison of the antihypertensive effects of betaxolol and chlorthalidone as monotherapy and in combination. Arch Intern Med. 1989 Nov;149(11):2437–2441.
   PubMedGoogle Scholar
• Rosenman RH. Combined clonidine-chlorthalidone therapy in hypertension. Two years’ experience in 30 patients. Arch Intern Med. 1975 Sep;135(9):1236–1239.
   PubMedGoogle Scholar
• Davis J, Oparil S. Novel medical treatments for hypertension and related comorbidities. Curr Hypertens Rep. 2018 Aug 25;20(10):90.
   PubMedGoogle Scholar
• Mroczek WJ, Lee WR, Davidov ME, et al. Clonidine and chlorthalidone (combipres) in hypertension. Curr Ther Res Clin Exp. 1975 Jan;17(1):47–53.
   PubMedGoogle Scholar
• Toubes DB, McIntosh TJ, Kirkendall WM, et al. Hypotensive effects of clonidine and chlorthalidone. Am Heart J. 1971;82(3):312–318.
   PubMedGoogle Scholar
• Weber MA, Sever P, Juhasz A, et al. A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone. J Renin Angiotensin Aldosterone Syst. 2018 Jul-Sep;19(3):1470320318795000.
   Google Scholar
• Collier DJ, Juhasz A, Agabiti-Rosei E, et al. Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: a randomized trial. J Clin Hypertens (Greenwich). 2018 Oct;20(10):1473–1484.
   PubMedGoogle Scholar
• Paton DM. Nebivolol/valsartan: fixed-dose combination for treatment of hypertension. Drugs Today (Barc). 2017 Jan;53(1):19–26.
   PubMedGoogle Scholar
• Lamberton NH, Copenhaver AM, Klassen A. Nebivolol/Valsartan (Byvalson) for hypertension. Am Fam Physician. 2018 Jan 15;97(2):124–125.
   PubMedGoogle Scholar
• Giles TD, Weber MA, Basile J, et al. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. Lancet. 2014;383(9932):1889–1898.
   PubMed Web of Science ®Google Scholar
• Glass G. Cardiovascular combinations. Nat Rev Drug Discov. 2004 Sep;3(9):731–732.
   PubMedGoogle Scholar
• Hennekens CH, Sacks FM, Tonkin A, et al. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med. 2004 Jan 12;164(1):40–44.
   PubMedGoogle Scholar
• Hradec J, Zamorano J, Sutradhar S. Post hoc analysis of the cluster randomized usual care versus caduet investigation assessing long-term risk (CRUCIAL) trial. Curr Med Res Opin. 2013 Jun;29(6):589–596.
   PubMed Web of Science ®Google Scholar
• Zamorano J, Erdine S, Pavia A, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial. Curr Med Res Opin. 2011 Apr;27(4):821–833.
   PubMed Web of Science ®Google Scholar
• Fedacko J, Pella D, Jarcuska P, et al. Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET(R) (the STRONG DUET study). Adv Ther. 2013 Jan;30(1):60–70.
   PubMedGoogle Scholar
• Fordyce CB, Giugliano RP, Cannon CP, et al. Cardiovascular events and long-term risk of sudden death among stabilized patients after acute coronary syndrome: insights from IMPROVE-IT. J Am Heart Assoc. 2022 Feb 15;11(4):e022733.
   PubMedGoogle Scholar
• Blazing MA, Giugliano RP, Cannon CP, et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014 Aug;168(2):205–12 e1.
   PubMedGoogle Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015 Jun 18;372(25):2387–2397.
   PubMedGoogle Scholar
• Vavlukis M, Vavlukis A. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs Context. 2018;7:212534.
   PubMedGoogle Scholar
• Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007 Jan;25(1):217–226.
   PubMed Web of Science ®Google Scholar
• Black HR, Kribben A, Aguirre Palacios F, et al. Aliskiren alone or in combination with hydrochlorothiazide in patients with the lower ranges of stage 2 hypertension: the ACQUIRE randomized double-blind study. J Clin Hypertens (Greenwich). 2010 Dec;12(12):917–926.
   PubMed Web of Science ®Google Scholar
• Blumenstein M, Romaszko J, Calderon A, et al. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. Curr Med Res Opin. 2009 Apr;25(4):903–910.
   PubMed Web of Science ®Google Scholar
• Grassi G. The ACQUIRE trial. Expert Opin Pharmacother. 2011 Jul;12(10):1665–1667.
   PubMed Web of Science ®Google Scholar
• Teo KK, Pfeffer M, Mancia G, et al. Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. Eur Heart J. 2014 Jul;35(26):1743–1751.
   PubMedGoogle Scholar
• Judd E, Jaimes EA. Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension. Expert Rev Cardiovasc Ther. 2012 Mar;10(3):293–303.
   PubMedGoogle Scholar
• Brown MJ, McInnes GT, Papst CC, et al. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet. 2011 Jan 22;377(9762):312–320.
   PubMedGoogle Scholar
• Ferdinand KC, Weitzman R, Israel M, et al. Efficacy and safety of aliskiren-based dual and triple combination therapies in US minority patients with stage 2 hypertension. J Am Soc Hypertens. 2011 Mar-Apr;5(2):102–113.
   PubMed Web of Science ®Google Scholar
• Weinberger MH, Izzo JL Jr., Purkayastha D, et al. Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension and obesity or metabolic syndrome. J Am Soc Hypertens. 2011 Nov-Dec;5(6):489–497.
   PubMed Web of Science ®Google Scholar
• Lancellotti P. Medication of the month. Exforge HCT: combination of amlodipine besylate, valsartan and hydrochlorothiazide in a single tablet. Rev Med Liege. 2010 Jul-Aug;65(7–8):471–475.
   PubMedGoogle Scholar
• Wang JG, Zeng WF, He YS, et al. Valsartan/amlodipine compared to nifedipine GITS in patients with hypertension inadequately controlled by monotherapy. Adv Ther. 2013 Aug;30(8):771–783.
   PubMedGoogle Scholar
• Epstein BJ, Shah NK, Borja-Hart NL. Management of hypertension with fixed-dose triple-combination treatments. Ther Adv Cardiovasc Dis. 2013 Oct;7(5):246–259.
   PubMedGoogle Scholar
• Oparil S, Melino M, Lee J, et al. Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther. 2010 Jul;32(7):1252–1269.
   PubMed Web of Science ®Google Scholar
• Patel A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–840.
   PubMed Web of Science ®Google Scholar
• Elliott WJ. Perindopril arginine + amlodipine for the treatment of hypertension in the USA. Expert Opin Pharmacother. 2015;16(14):2217–2229.
   PubMed Web of Science ®Google Scholar
• Fleig SV, Weger B, Haller H, et al. Effectiveness of a fixed-dose, single-pill combination of perindopril and amlodipine in patients with hypertension: a non-interventional study. Adv Ther. 2018 Mar;35(3):353–366.
   PubMedGoogle Scholar
• Nedogoda SV, Stojanov VJ. Single-pill combination of Perindopril/Indapamide/Amlodipine in patients with uncontrolled hypertension: a randomized controlled trial. Cardiol Ther. 2017 Jun;6(1):91–104.
   PubMedGoogle Scholar
• Mazza A, Townsend DM, Schiavon L, et al. Long-term effect of the perindopril/indapamide/amlodipine single-pill combination on left ventricular hypertrophy in outpatient hypertensive subjects. Biomed Pharmacother. 2019 Dec;120:109539.
   PubMed Web of Science ®Google Scholar
• Marazzi G, Pelliccia F, Campolongo G, et al. Greater cardiovascular risk reduction with once-daily fixed combination of three antihypertensive agents and statin versus free-drug combination: the ALL-IN-ONE trial. Int J Cardiol. 2016 Nov 1;222:885–887.
   PubMedGoogle Scholar
• Toth K, Investigators P. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014 Apr;14(2):137–145.
   PubMedGoogle Scholar
• Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015 Aug 27;373(9):834–844.
   PubMedGoogle Scholar
• Hassoun PM, Zamanian RT, Damico R, et al. Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015 Nov 1;192(9):1102–1110.
   PubMedGoogle Scholar
• Fala L. Entresto (Sacubitril/Valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure. Am Health Drug Benefits. 2015 Sep;8(6):330–334.
   PubMedGoogle Scholar
• Yandrapalli S, Khan MH, Rochlani Y, et al. Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy. Ther Adv Cardiovasc Dis. 2018 Aug;12(8):217–231.
   PubMedGoogle Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11;371(11):993–1004.
   PubMed Web of Science ®Google Scholar
• Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003 Oct 14;108(15):1831–1838.
   PubMedGoogle Scholar
• Goldstein JL, Whellan DJ, Scheiman JM, et al. Long-term safety of a coordinated delivery tablet of enteric-coated aspirin 325 mg and Immediate-release omeprazole 40 mg for secondary cardiovascular disease prevention in patients at GI risk. Cardiovasc Ther. 2016 Apr;34(2):59–66.
   PubMedGoogle Scholar
• Veltri KT. Yosprala: a fixed dose combination of aspirin and omeprazole. Cardiol Rev. 2018 January/February;26(1):50–53.
   PubMedGoogle Scholar
• Ingram CA, Giang G, McCrory K, et al. Yosprala: coordinated delivery of a proton pump inhibitor and aspirin. J Pharm Technol. 2020 Apr;36(2):78–83.
   PubMedGoogle Scholar
• Whellan DJ, Goldstein JL, Cryer BL, et al. PA32540 (a coordinated-delivery tablet of enteric-coated aspirin 325 mg and immediate-release omeprazole 40 mg) versus enteric-coated aspirin 325 mg alone in subjects at risk for aspirin-associated gastric ulcers: results of two 6-month, phase 3 studies. Am Heart J. 2014 Oct;168(4):495–502 e4.
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036–1046.
   PubMed Web of Science ®Google Scholar
• Group ASC, Bowman L, Mafham M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018 Oct 18;379(16):1529–1539.
   PubMedGoogle Scholar
• Zhou YH, Wei X, Lu J, et al. Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. PLoS One. 2012;7(2):e31642.
   PubMedGoogle Scholar
• Yusuf S, Joseph P, Dans A, et al. Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med. 2021 Jan 21;384(3):216–228.
   PubMedGoogle Scholar
• Arnott C, Neuen BL, Heerspink HJL, et al. The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program. Int J Cardiol. 2020 Nov 1;318:126–129.
   PubMedGoogle Scholar
• Munoz D, Uzoije P, Reynolds C, et al. Polypill for cardiovascular disease prevention in an underserved population. N Engl J Med. 2019 Sep 19;381(12):1114–1123.
   PubMedGoogle Scholar
• Macaulay TE, Sheridan E, Ward S. Reconsidering the polypill for management of cardiovascular risk factors in underserved patients. Curr Cardiol Rep. 2021 Feb 17;23(3):19.
   PubMedGoogle Scholar
• Burnett JR. Torcetrapib + atorvastatin (Pfizer). Curr Opin Invest Drugs. 2005 Sep;6(9):944–950.
   PubMedGoogle Scholar
• Bays H, McKenney J, Davidson M. Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther. 2005 Sep;3(5):789–820.
   PubMedGoogle Scholar
• Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):257–260.
   PubMedGoogle Scholar
• Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007 Apr 19;356(16):1620–1630.
   PubMedGoogle Scholar
• Khera AV, Plutzky J. Management of low levels of high-density lipoprotein-cholesterol. Circulation. 2013 Jul 2;128(1):72–78.
   PubMedGoogle Scholar
• Nurmohamed NS, Ditmarsch M, Kastelein JJP. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Cardiovasc Res. 2021. DOI:10.1093/cvr/cvab350
   PubMedGoogle Scholar
• Choi HD, Chae SM. Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia: a systematic review and meta-analysis. Medicine (Baltimore). 2018 Dec;97(50):e13593.
   PubMedGoogle Scholar
• Dayar E, Pechanova O. Targeted strategy in lipid-lowering therapy. Biomedicines. 2022 May 8;10(5):1090.
   PubMedGoogle Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532–2561.
   PubMed Web of Science ®Google Scholar
• Klassen A, Faccio AT, Picossi CRC, et al. Evaluation of two highly effective lipid-lowering therapies in subjects with acute myocardial infarction. Sci Rep. 2021 Aug 5;11(1):15973.
   PubMedGoogle Scholar
• Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018 Jul 17;72(3):330–343.
   PubMedGoogle Scholar
• Maki KC, Bays HE, Dicklin MR, et al. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J Clin Lipidol. 2011 Nov-Dec;5(6):483–492.
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–1098.
   PubMed Web of Science ®Google Scholar
• Patel D, Busch R. Omega-3 fatty acids and cardiovascular disease: a narrative review for pharmacists. J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):524–532.
   PubMedGoogle Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11–22.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Brinton EA, et al. Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial. Clin Cardiol. 2017 Mar;40(3):138–148.
   PubMed Web of Science ®Google Scholar
• Hernandez P, Passi N, Modarressi T, et al. Clinical management of hypertriglyceridemia in the prevention of cardiovascular disease and pancreatitis. Curr Atheroscler Rep. 2021 Sep 13;23(11):72.
   PubMedGoogle Scholar
• Arai H, Yamashita S, Yokote K, et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis. 2017 Jun;261:144–152.
   PubMed Web of Science ®Google Scholar
• Araki E, Yamashita S, Arai H, et al. Effects of pemafibrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with Type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, Phase 3 trial. Diabetes Care. 2018 Mar;41(3):538–546.
   PubMed Web of Science ®Google Scholar
• Investigators A-H. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (Aim-HIGH). Am Heart J. 2011 Mar;161(3):471–477 e2.
   PubMedGoogle Scholar
• Guyton JR, Slee AE, Anderson T, et al. Relationship of lipoproteins to cardiovascular events: the Aim-HIGH trial (Atherothrombosis intervention in metabolic syndrome with low HDL/High triglycerides and impact on global health outcomes). J Am Coll Cardiol. 2013 Oct 22;62(17):1580–1584.
   PubMedGoogle Scholar
• Vargason AM, Anselmo AC, Mitragotri S. The evolution of commercial drug delivery technologies. Nat Biomed Eng. 2021 Sep;5(9):951–967.
   PubMed Web of Science ®Google Scholar
• Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018 Sep 19;16(1):71.
   PubMed Web of Science ®Google Scholar
• Tabanelli R, Brogi S, Calderone V. Improving curcumin bioavailability: current strategies and future perspectives. Pharmaceutics. 2021 Oct 17;13(10):1715.
   PubMedGoogle Scholar
• Lomis N, Gaudreault F, Malhotra M, et al. Novel milrinone nanoformulation for use in cardiovascular diseases: preparation and in vitro characterization. Mol Pharm. 2018 Jul 2;15(7):2489–2502.
   PubMedGoogle Scholar
• Andrews GP, Li S, Almajaan A, et al. Fixed dose combination formulations: multilayered platforms designed for the management of cardiovascular disease. Mol Pharm. 2019 May 6;16(5):1827–1838. .
   PubMedGoogle Scholar
• Erakovic Haber V, Spaventi R. Discovery and development of novel drugs. Prog Mol Subcell Biol. 2017;55:91–104.
   PubMedGoogle Scholar
• Lundstrom K. Epigenetics: new possibilities for drug discovery. Future Med Chem. 2017 Apr;9(5):437–441.
   PubMedGoogle Scholar
• Holdgate GA, Bardelle C, Lanne A, et al. Drug discovery for epigenetics targets. Drug Discov Today. 2021 Oct 30;27(4):1088–1098.
   PubMedGoogle Scholar
• Dutta P, Sengupta A, Chakraborty S. Epigenetics: a new warrior against cardiovascular calcification, a forerunner in modern lifestyle diseases. Environ Sci Pollut Res Int. 2021 Oct 2. DOI:10.1007/s11356-021-15718-0
   Google Scholar
• Liu CF, Tang WHW. Epigenetics in cardiac hypertrophy and heart failure. JACC Basic Transl Sci. 2019 Dec;4(8):976–993. .
   PubMedGoogle Scholar
• Brindisi M, Saraswati AP, Brogi S, et al. Old but gold: tracking the new guise of histone deacetylase 6 (HDAC6) enzyme as a biomarker and therapeutic target in rare diseases. J Med Chem. 2020 Jan 9;63(1):23–39.
   PubMedGoogle Scholar
• Campiani G, Cavella C, Osko JD, et al. Harnessing the role of HDAC6 in idiopathic pulmonary fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors. J Med Chem. 2021 Jul 22;64(14):9960–9988.
   PubMedGoogle Scholar
• Lei H, Hu J, Sun K, et al. The role and molecular mechanism of epigenetics in cardiac hypertrophy. Heart Fail Rev. 2021 Nov;26(6):1505–1514.
   PubMedGoogle Scholar
• Micheu MM, Birsan MV, Szep R, et al. From air pollution to cardiovascular diseases: the emerging role of epigenetics. Mol Biol Rep. 2020 Jul;47(7):5559–5567.
   PubMedGoogle Scholar
• Keating ST, Plutzky J, El-Osta A. Epigenetic changes in diabetes and cardiovascular risk. Circ Res. 2016 May 27;118(11):1706–1722.
   PubMedGoogle Scholar
• Molokie R, Lavelle D, Gowhari M, et al. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study. PLoS Med. 2017 Sep;14(9):e1002382.
   PubMed Web of Science ®Google Scholar
• Watson CJ, Horgan S, Neary R, et al. Epigenetic therapy for the treatment of hypertension-induced cardiac hypertrophy and fibrosis. J Cardiovasc Pharmacol Ther. 2016 Jan;21(1):127–137.
   PubMed Web of Science ®Google Scholar
• Xiao D, Dasgupta C, Chen M, et al. Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats. Cardiovasc Res. 2014 Mar 1;101(3):373–382.
   PubMedGoogle Scholar
• Consalvi S, Saccone V, Mozzetta C. Histone deacetylase inhibitors: a potential epigenetic treatment for Duchenne muscular dystrophy. Epigenomics. 2014;6(5):547–560.
   PubMedGoogle Scholar
• Milan M, Pace V, Maiullari F, et al. Givinostat reduces adverse cardiac remodeling through regulating fibroblasts activation. Cell Death Dis. 2018 Jan 25;9(2):108.
   PubMedGoogle Scholar
• Najafova Z, Tirado-Magallanes R, Subramaniam M, et al. BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire. Nucleic Acids Res. 2017 Jan 9;45(1):127–141.
   PubMedGoogle Scholar
• Baud’huin M, Lamoureux F, Jacques C, et al. Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. Bone. 2017 Jan;94:10–21.
   PubMed Web of Science ®Google Scholar
• Gilham D, Tsujikawa LM, Sarsons CD, et al. Apabetalone downregulates factors and pathways associated with vascular calcification. Atherosclerosis. 2019 Jan;280:75–84.
   PubMed Web of Science ®Google Scholar
• Polak JM, Bishop AE. Stem cells and tissue engineering: past, present, and future. Ann N Y Acad Sci. 2006 Apr;1068(1):352–366.
   PubMedGoogle Scholar
• Burridge PW, Keller G, Gold JD, et al. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell. 2012 Jan 6;10(1):16–28. .
   PubMedGoogle Scholar
• Yang X, Rodriguez M, Pabon L, et al. Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. J Mol Cell Cardiol. 2014 Jul;72:296–304.
   PubMed Web of Science ®Google Scholar
• Cao N, Liu Z, Chen Z, et al. Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells. Cell Res. 2012 Jan;22(1):219–236.
   PubMed Web of Science ®Google Scholar
• Zhu WZ, Xie Y, Moyes KW, et al. Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells. Circ Res. 2010 Sep 17;107(6):776–786.
   PubMedGoogle Scholar
• Sun X, Nunes SS. Biowire platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Methods. 2016 May 15;101:21–26
   PubMedGoogle Scholar
• Feric NT, Pallotta I, Singh R, et al. Engineered cardiac tissues generated in the biowire ii: a platform for human-based drug discovery. Toxicol Sci. 2019 Aug 6;172(1):89–97.
   PubMedGoogle Scholar
• Yokoo N, Baba S, Kaichi S, et al. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. Biochem Biophys Res Commun. 2009 Sep 25;387(3):482–488.
   PubMedGoogle Scholar
• Kadota S, Minami I, Morone N, et al. Development of a reentrant arrhythmia model in human pluripotent stem cell-derived cardiac cell sheets. Eur Heart J. 2013 Apr;34(15):1147–1156.
   PubMedGoogle Scholar
• Mohammadi MH, Obregon R, Ahadian S, et al. Engineered muscle tissues for disease modeling and drug screening applications. Curr Pharm Des. 2017;23(20):2991–3004.
   PubMedGoogle Scholar
• Ulmer BM, Stoehr A, Schulze ML, et al. Contractile work contributes to maturation of energy metabolism in hiPSC-derived cardiomyocytes. Stem Cell Reports. 2018 Mar 13;10(3):834–847.
   PubMedGoogle Scholar
• Nunes SS, Miklas JW, Liu J, et al. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat Methods. 2013 Aug;10(8):781–787.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Rafatian N, Feric NT, et al. A platform for generation of chamber-specific cardiac tissues and disease modeling. Cell. 2019 Feb 7;176(4):913–927 e18.
   PubMedGoogle Scholar
• Teerlink JR, Felker GM, McMurray JJV, et al. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016;388(10062):2895–2903.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Felker GM, McMurray JJV, et al. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study. J Am Coll Cardiol. 2016 Mar 29;67(12):1444–1455.
   PubMedGoogle Scholar
• Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016 Feb 5;351(6273):617–621.
   PubMedGoogle Scholar
• Zheng Y, Chen J, Craven M, et al. In vitro microvessels for the study of angiogenesis and thrombosis. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9342–9347.
   PubMedGoogle Scholar
• Kolesky DB, Truby RL, Gladman AS, et al. 3D bioprinting of vascularized, heterogeneous cell-laden tissue constructs. Adv Mater. 2014;26(19):3124–3130.
   PubMed Web of Science ®Google Scholar
• Raju R, Loskill P, Marcus SG, et al. μOrgano: a Lego®-Like plug & play system for modular multi-organ-chips. Plos One. 2015;10(10):e0139587.
   PubMedGoogle Scholar
• Islam MM, Beverung S, Steward Jr R Jr. Bio-inspired microdevices that mimic the human vasculature. Micromachines. 2017;8(10):299.
   PubMedGoogle Scholar
• Zhu W, Qu X, Zhu J, et al. Direct 3D bioprinting of prevascularized tissue constructs with complex microarchitecture. Biomaterials. 2017 Apr;124:106–115.
   PubMed Web of Science ®Google Scholar
• Lai BFL, Huyer LD, Rxz L, et al. InVADE: integrated vasculature for assessing dynamic events. Adv Funct Mater. 2017;27(46):1703524.
   Google Scholar
• Figtree GA, Bubb KJ, Tang O, et al. Vascularized cardiac spheroids as novel 3D in vitro models to study cardiac fibrosis. Cells Tissues Organs. 2017;204(3–4):191–198.
   PubMedGoogle Scholar
• Kim S, Kim W, Lim S, et al. Vasculature-on-a-chip for in vitro disease models. Bioengineering (Basel). 2017 Jan 24;4(1). DOI:10.3390/bioengineering4010008.
   Google Scholar
• Kapetanovic IM. Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach. Chem Biol Interact. 2008 Jan 30;171(2):165–176.
   PubMedGoogle Scholar
• Balasubramanian K. Mathematical and computational techniques for drug discovery: promises and developments. Curr Top Med Chem. 2018;18(32):2774–2799.
   PubMed Web of Science ®Google Scholar
• Gintant G, Fermini B, Stockbridge N, et al. The evolving roles of human iPSC-derived cardiomyocytes in drug safety and discovery. Cell Stem Cell. 2017 Jul 6;21(1):14–17.
   PubMedGoogle Scholar
• Li Z, Dutta S, Sheng J, et al. Improving the in silico assessment of proarrhythmia risk by combining hERG (Human ether-a-go-go-related gene) Channel-drug binding kinetics and multichannel pharmacology. Circ Arrhythm Electrophysiol. 2017 Feb;10(2):e004628.
   PubMedGoogle Scholar
• Lancaster MC, Sobie EA. Improved prediction of drug-induced torsades de pointes through simulations of dynamics and machine learning algorithms. Clin Pharmacol Ther. 2016 Oct;100(4):371–379.
   PubMed Web of Science ®Google Scholar
• Shim JV, Chun B, van Hasselt JGC, et al. Mechanistic systems modeling to improve understanding and prediction of cardiotoxicity caused by targeted cancer therapeutics. Front Physiol. 2017;8:651.
   PubMedGoogle Scholar
• Sharma A, Burridge PW, McKeithan WL, et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med. 2017 Feb 15;9(377). DOI:10.1126/scitranslmed.aaf2584.
   Google Scholar
• de Oliveira BL, Niederer S. A biophysical systems approach to identifying the pathways of acute and chronic doxorubicin mitochondrial cardiotoxicity. PLoS Comput Biol. 2016 Nov;12(11):e1005214.
   PubMed Web of Science ®Google Scholar
• Helmlinger G, Sokolov V, Peskov K, et al. Quantitative systems pharmacology: an exemplar model-building workflow with applications in cardiovascular, metabolic, and oncology drug development. CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):380–395.
   PubMedGoogle Scholar
• Cheng L, Qiu Y, Schmidt BJ, et al. Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure. J Pharmacokinet Pharmacodyn. 2022 Feb;49(1):39–50.
   PubMedGoogle Scholar
• Leil TA, Ermakov SE. The emerging discipline of quantitative systems pharmacology. Front Pharmacol. 2015;6:129.
   PubMedGoogle Scholar